Identification of a clinical signature predictive of differentiation fate of human bone marrow stromal cells

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Background: Transplantation of human bone marrow stromal cells (hBMSCs) is a promising therapy for bone regeneration due to their ability to differentiate into bone forming osteoblastic cells. However, transplanted hBMSCs exhibit variable capacity for bone formation resulting in inconsistent clinical outcome. The aim of the study was to identify a set of donor- and cell-related characteristics that detect hBMSCs with optimal osteoblastic differentiation capacity. Methods: We collected hBMSCs from 58 patients undergoing surgery for bone fracture. Clinical profile of the donors and in vitro characteristics of cultured hBMSCs were included in uni- and multivariable analysis to determine their predictive value for osteoblastic versus adipocytic differentiation capacity assessed by quantification of mineralized matrix and mature adipocyte formation, respectively. Results: We identified a signature that explained > 50% of variation in osteoblastic differentiation outcome which included the following positive predictors: donor sex (male), absence of osteoporosis diagnosis, intake of vitamin D supplements, higher fraction of CD146+, and alkaline phosphate (ALP+) cells. With the exception of vitamin D and ALP+ cells, these variables were also negative predictors of adipocytic differentiation. Conclusions: Using a combination of clinical and cellular criteria, it is possible to predict differentiation outcome of hBMSCs. This signature may be helpful in selecting donor cells in clinical trials of bone regeneration.

OriginalsprogEngelsk
Artikelnummer265
TidsskriftStem Cell Research and Therapy
Vol/bind12
Antal sider15
ISSN1757-6512
DOI
StatusUdgivet - 2021

Bibliografisk note

Funding Information:
The study was carried out as a part of BONEBANK project (project number: 16-1.0-15), supported by Interreg 5a Germany-Denmark, the European Regional Development, The NovoNordisk Foundation NNF (180C0054118), and the Lundbeck foundation (R266-2017-4250).

Funding Information:
Interreg European Regional Development (16-1.0-15), The NovoNordisk Foundation NNF (180C0054118), Lundbeck foundation (R266-2017-4250).

Publisher Copyright:
© 2021, The Author(s).

ID: 262795458